Thiosemicarbazones: the new wave in cancer treatment (Q37855829)

24 August 2017

1 reference

title

Thiosemicarbazones: the new wave in cancer treatment (English)

1 reference

24 August 2017

1

1 reference

24 August 2017

3

1 reference

24 August 2017

2

Patricia Quach

1 reference

24 August 2017

publication date

1 September 2009

1 reference

Future Medicinal Chemistry

24 August 2017

published in

1 reference

24 August 2017

volume

1

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

1143-1151

1 reference

The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes.

24 August 2017

cites work

1 reference

Reduction of Ribonucleotides

21 January 2018

1 reference

Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors

21 January 2018

1 reference

p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia

21 January 2018

1 reference

The evolution of iron chelators for the treatment of iron overload disease and cancer.

21 January 2018

1 reference

Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy

21 January 2018

1 reference

Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.

21 January 2018

1 reference

2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.

21 January 2018

1 reference

Neurodegenerative diseases and oxidative stress

21 January 2018

1 reference

Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency

21 January 2018

1 reference

Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

21 January 2018

1 reference

Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity

21 January 2018

1 reference

Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.

21 January 2018

1 reference

Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation

21 January 2018

1 reference

A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase

21 January 2018

1 reference

A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics

21 January 2018

1 reference

Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.

21 January 2018

1 reference

A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

21 January 2018

1 reference

A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye

21 January 2018

1 reference

Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

21 January 2018

1 reference

Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs

21 January 2018

1 reference

Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells

21 January 2018

1 reference

Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents

21 January 2018

1 reference

Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion

21 January 2018

1 reference

Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation

21 January 2018

1 reference

Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression

21 January 2018

1 reference

Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells

21 January 2018

1 reference

The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells

21 January 2018

1 reference

Synergistic Interaction of Kethoxal bis(Thiosemicarbazone) and Cupric Ions in Sarcoma 180

21 January 2018

1 reference

Sites of Inhibition of DNA Synthesis by Kethoxal bis(Thiosemicarbazone)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/FMC.09.80

1 reference

24 August 2017

1 reference